NEU 2.50% $15.59 neuren pharmaceuticals limited

Pending ROW deal??, page-178

  1. 114 Posts.
    lightbulb Created with Sketch. 147
    Just a couple of points. The milestone payments are one-off so shouldn't be included in revenue for valuation purposes as they do not recur in subsequent years. That brings the revenue back to $1.8bn. The current structure for North America has graduated royalties averaging at about 12.5% and I see no reason why they would hit 15% overall as this would presuppose a top rate in ROW of about 25%, which seems unlikely. So lets keep them at 12.5%. That would give $US225 million revenues or about $AU338 million. Knock off 40% for overheads, and this gives an EPS of about $1.60 per share. Using your multiplier of 20 P/E that still brings it out to $32 per share; a realistic and still impressive figure based on Daybue alone. Throw in the blue sky of NNZ2591 and this share has lots more to offer. Although I must say I wonder why a buyer would pay 20 times current earnings per share for an income stream that has 7 years to go in the US and 10 in Europe..
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$15.59
Change
0.380(2.50%)
Mkt cap ! $1.992B
Open High Low Value Volume
$15.51 $15.82 $15.46 $11.26M 722.0K

Buyers (Bids)

No. Vol. Price($)
1 696 $15.59
 

Sellers (Offers)

Price($) Vol. No.
$15.67 6942 8
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.